This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 1998;279:818.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A 2-month course of therapy to prevent active tuberculosis in patients infected with the human immunodeficiency virus (HIV) is an effective alternative to the 12-month regimen currently recommended for people coinfected with HIV and tuberculosis (TB), according to a study of nearly 1600 patients in 4 countries. More than 5 million people worldwide are infected with both HIV and Mycobacterium tuberculosis and are at high risk of developing active TB.

The multinational effort was sponsored by the National Institute of Allergy and Infectious Diseases, the Pan American Health Organization, and the Centers for Disease Control and Prevention. Preliminary results of the study were presented last month at the Fifth Conference on Retroviruses and Opportunistic Infections in Chicago, Ill.

Currently, a year-long prophylactic regimen of isoniazid is recommended for patients who are coinfected with HIV and M tuberculosis. "But poor compliance limits the effectiveness of this regimen," . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?